| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C22H15FN4O2S |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
CAY10602 is a SIRT1 activator that dose-dependently suppresses the NF-κB-dependent induction of TNF-α by lipopolysaccharide in THP-1 cells[1]. It is supplied as a white to gray solid (C22H15FN4O2S, MW 418.44) at 98.69% purity.
Physical & Chemical Properties
| CAS Number | 374922-43-7 |
|---|---|
| Molecular Formula | C22H15FN4O2S |
| Molecular Weight | 418.44 g/mol |
| Purity | 98.69% |
| Appearance | Solid |
| Color | White to gray |
| SMILES | NC1=C(S(=O)(C2=CC=CC=C2)=O)C3=NC4=CC=CC=C4N=C3N1C5=CC=C(F)C=C5 |
| Target | SIRT1 |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics |
| Solubility | In Vitro: DMSO: 41.67 mg/mL (99.58 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 41.67 mg/mL (99.58 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.08 mg/mL (4.97 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.08 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (20.8 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Data provided by the manufacturer.
In Vitro
SIRT1-activating compounds (including CAY10602) significantly affect fat mobilization in differentiated adipocytes and have antiobesity and/or antidiabetic properties. At concentrations between 20 and 60 μM, SIRT1-activating compounds (including CAY10602) strongly suppress TNF-α release[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[1]
Culture 3T3L1 mouse fibroblasts and THP-1 leukemia cells according to the supplier’s recommendations. Treat THP-1 cells first with representative compounds (including CAY10602), then add lipopolysaccharide (LPS). Plate THP-1 cells in 24-well culture plates, using 0.4 mL (0.5×106 cells/treatment) at a density of 1.2×106 cells/mL. Preincubate the cells for 1 h under general tissue culture conditions with 2 concentrations (20 or 60 μM) of representative test compounds (including CAY10602)[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells. Cell Death Dis 2019 Apr 15;10(5):331.
Dehydrodiisoeugenol alleviates palmitate-induced mitochondrial dysfunction in human vascular smooth muscle cells through the activation of SIRT1-mediated Drp1 deacetylation. Lipids Health Dis 2025 May 24;24(1):187. PMID: 40413480
Elucidation of SIRT-1/PGC-1α-associated mitochondrial dysfunction and autophagy in nonalcoholic fatty liver disease. Lipids Health Dis 2021 Apr 26;20(1):40. PMID: 33902605
Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis. J Agric Food Chem 2024 Nov 6;72(44):24400-24416. PMID: 39440960
High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway. Cancers (Basel) 2023 Apr 23;15(9):2427. PMID: 37173894
A Deacetylase Cq SIRT1 Promotes WSSV Infection by Binding to Viral Envelope Proteins in Cherax quadricarinatus. Viruses 2022 Aug 6;14(8):1733. PMID: 36016356
BPDE and B[a]P induce mitochondrial compromise by ROS-mediated suppression of the SIRT1/TERT/PGC-1α pathway in spermatogenic cells both in vitro and in vivo. Toxicol Appl Pharmacol 2019 Aug 1:376:17-37. PMID: 31085209
Role of SIRT1 in Hepatic Encephalopathy: In Vivo and In Vitro Studies Focusing on the NLRP3 Inflammasome. Oxid Med Cell Longev 2021 Oct 12:2021:5522708. PMID: 34676022
